Merck Case Study

In: Business and Management

Submitted By dalmis04
Words 2468
Pages 10
Case Study: Merck Acquisition of Medco
Professor Daniel Weiss
January 23, 2011
DeVry University

Case Study: Merck Acquisition of Medco


The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United States would result in a successful campaign to take over the drug industry if handled appropriately. As Chairman and CEO of Merck Corporation, I have to consider all sides of the arguments, financially, marketing and cultural wise and come to a conclusion as to whether this merger would be a good idea for the company. Like any other investment and merger, there are risks, and I have to decide what would be best in the interest of this company. The details as to whether the decision to acquire or not acquire Medco will be described in this paper. Along with data that helps make that final decision.

There are a few things one must take into account before making a decision. You have to look at the long term run, whether or not the merger and acquisition will be successful. You also have to take synergy into account; it is the most important reason why there are a lot of mergers and acquisitions. Synergy would be when two companies join forces to create additional value and cut costs that would be unnecessary. You would also have to take into account changes in forces, like technological changes, economies of scales, type of merger you want to have and the process it takes to make a decision especially when it comes to a merger and acquisition worth millions if not billions of dollars. In the case of Merck and Medco, the role of prescription benefits management companies…...

Similar Documents

Merck Case Question

...Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next, if Merck decides to pursue license, they go into phase I which results in a success, or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone, weight loss alone, or both, or contemplate phase II failure. Finally phase II success for different options leads to phase III, and there are success or failure related outcomes for each of the alternatives in phase II (i.e. developing the drug to treat depression, weight loss, or both). HINTS: Within each phase, remember that the probabilities of various outcomes (including failure, which is not always mentioned as an option) should add up to 100%. In each phase, the stated cost already includes fees paid to LAB. For example, cost of Phase I is $30 million (this number includes $5 million paid to LAB). A careful read of the case is critical to get the tree, various probabilities and the cash flows right. Please be sure to include your decision tree along with your answer to the questions below. 1) What is the expected value in launching Davarink as an antidepressant only? 2) What is the expected value in launching Davarink to treat only weight loss? 3) What is the expected value in launching Davarink for possibility of separate...

Words: 423 - Pages: 2

Case Study Merck Acquisition

...Case FIN561: Mergers and Acquisitions You decide: Merck Acquition of Medco Vikash Sharma In July 1993, Merck & Co., the largest pharmaceutical company in the world at that time, acquired Medco Containment Services for $6.6 billion. Medco was the largest prescription benefits management company. With the drug industry experiencing the effects of managed care, pharmaceutical companies had to adapt to new means of distribution. Merck realized that the decisions of what treatments and what drugs should be used in patients’ care were increasingly being influenced by the managed care environment rather than by physicians. In the world of managed care, it was no longer sufficient to market just to physicians. The successful pharmaceutical companies of the future would be companies that were able to adapt to the changed distribution system. This was a very strategic move my Merck and this vertical integration was a move that all its competitors were also targeting. In 1994 SmithKline acquired DPS for $2.2B and later that year Eli Lily acquired PCS for $4.1B. In order to understand why Merck acquired Medco, which was a pharmacy benefits management (PBM) company, we need to look at the role of this so-called PBM’s. These PBM’s have several functions * Process Pharmacy claims i.e. check for eligibility when an order is placed at the retail store, check for copayment etc * Set up Pharmacy benefit, which is to apply PBM codes to what drugs are covered under a......

Words: 973 - Pages: 4

Case Study Case Study Case Study

...This case study is an excellent example of how different types of parties can be brought together in a large scale transaction and how the original energy of those early meetings can be lost over time. I imagine that when Anthony Athanas was purchasing those old piers back in the 1960s many, if not all, of his colleagues, friends, and family members told him that he was off his rocker. I’m sure Athanas was looking at this land as his family’s ticket to financial prosperity and somewhat of a legacy that he could leave to his descendants for years and years to come. One of the items I wish the case would have divulged is the amount of money that Athanas had invested in the properties. For me this information would have given an insight to his net worth and how much he had riding on this investment. I assume it was substantial given his actions later in the process. Twenty years later Athanas’ dreams came true and all those naysayers were more than likely green with envy. The amount of pride Athanas’ had in his investment at that moment had to have been insurmountable. Being approached by a big time real estate development company and their extremely wealthy client, Hyatt Corporation, must have made Athanas feel larger than life and made him feel like something he isn’t, which is a developer himself. The case doesn’t give much insight into whether Athanas had any representation or anyone consulting him throughout the process. From the beginning, I saw this as matchup...

Words: 1190 - Pages: 5

Merck Case Analysis

...Stakeholder Analysis – Merck Identify Key Stakeholders In the pharmaceutical industry, there is much to consider and constantly change in order to continue profits. In order to continue profits, a main factor, as said by former Merck president George W Merck, is the people. Merck said, “We try to never forget that medicine is for the people”. The first group of stakeholders has to be the people, or the consumer. The consumer is actually using the product from Merck and Co. and ultimately determines the success of the business. The second group of stakeholders is the employees. Employees determine the performance of the company. The employees consist of the executives and the lower management. A third group is the research and developers. A new drug must be created in order for the company to succeed. Ray Gilmartin, CEO, invests millions to create new drugs for Merck. One important example is the race to create one’s own Cox-2-inhibiting painkiller. A fourth group of key stakeholders is the doctors. Sales representatives try to sell Merck’s product to doctor’s offices. $102 million was spent just on sales representatives. Successful sales representatives lead to doctors writing prescriptions to patients for Merck’s products. Lastly, investors are a key stakeholder. An investor in the business cares about the downfalls and upcoming of a company because it is their money. The investor wants to receive a return on their initial investment and for the company to do......

Words: 600 - Pages: 3

Merck Case Study

...Εισαγωγή Η αρχή της δεκαετίας του 1990 αποτέλεσε για τις φαρμακευτικές βιομηχανίες το χρονικό ορόσημο, όπου άλλαξαν δραματικά τα δεδομένα ανάπτυξης και κερδοφορίας για το συγκεκριμένο χώρο σε παγκόσμιο επίπεδο. Έτσι παρατηρήθηκαν, σημαντικές μειώσεις στις πωλήσεις φαρμάκων και συνεπώς των κερδών, καθώς και πολύ μεγάλες πτώσεις στις τιμές των μετοχών των εταιρειών που δραστηριοποιούνταν στο συγκεκριμένο αντικείμενο. Μία από τις κυρίαρχες εταιρείες του χώρου των φαρμάκων η οποία επηρεάστηκε σημαντικά από τις εξελίξεις της δεκαετίας ήταν η Merck. Αν συλλογιστεί κανείς ότι ο συγκεκριμένος κλάδος προερχόταν από μία περίοδο τεράστιας άνθισης της κερδοφορίας (πριν το 1990), αξίζει να γίνει μία ανάλυση των αιτιών που οδήγησαν σε αυτήν την αρνητική μεταστροφή διερευνώντας τόσο το εξωτερικό όσο και το εσωτερικό περιβάλλον της εταιρείας. Προκλήσεις εταιρείας Αναλύοντας το εξωτερικό μακροπεριβάλλον, θα πρέπει να σταθεί κανείς στη νομοθετική ρύθμιση των Waxman-Hatch (1984) στις Η.Π.Α. κατά την οποία μειώθηκαν ουσιαστικά τα εμπόδια εισόδου των γενοσήμων φαρμάκων (generics) στην αγορά. Με τη νομοθετική αυτή ρύθμιση, επιταγχύνθηκαν δραστικά οι διαδικασίες εγκρίσεων των φαρμάκων αυτού του τύπου, καθώς δεν απαιτούνταν πλέον χημικοί και βιολογικοί έλεγχοι προκειμένου να κυκλοφορήσουν στην αγορά. Έτσι, οι εταιρείες παρασκευής των γενοσήμων φαρμάκων, απουσία των κλινικών δοκιμών αλλά και των δαπανών για την έρευνα καθώς πρόκειται για αντιγραφές φαρμάκων, είχαν σημαντικές μειώσεις στα......

Words: 237 - Pages: 1

Merck Acquisition of Medco Study and Analysis

...Merck Acquisition of Medco Study and Analysis Abstract Corporate mergers and acquisitions (M&A) have become popular across the globe during the last two decades due to globalization, liberalization, technological developments, and competitive business environment (Fisher & Siburg, 2009). The synergistic gains from M&A may result from efficient management, economies of scale, profitable use of assets, exploitation of market power, and the use of complementary resources (Mitchell et al, 2004). Theoretically it is assumed that mergers improve the performance of the acquiring firm due to increased market share and synergy impact. This paper reviews the acquisition of Medco Medco Containment Services, Inc. (Medco) by Merck & Company (Merck) and cites reasons for acquisition of Medco. Merck's acquisition of Medco represents a $6.6 billion bet on where the future of the pharmaceutical industry lies (Nichols, 1994). In today's managed-care environment, Vagelos (CEO of Merck in 1993) argues, the company that best controls the information flow from doctor to patient to pharmacist to plan sponsor has the greatest chance of succeeding. Medco has information on 38 million patients, which allows Merck to learn a lot more about how its drugs are prescribed and used and, ultimately, how effective they are in fighting disease. Owning Medco can also help Merck increase its market share in an industry in which no company......

Words: 2407 - Pages: 10

Merck Case Study

...Merck & Costa Rica Case Study Rory S Smith Ethics in Global Environment State University of New York Empire State College Introduction Companies globally are often times scrutinize for their business practices. They face strong opposition and public humiliation when they conduct their business in an unethical way. When companies operate globally, they must ensure they are operating in a socially responsible manner. Being socially responsible is not just giving back to the local community but to be aware of any unforeseen threats that may affect the business. Many countries around the world do not have strict laws governing the preservation of their natural resources. Global companies see this to their advantage to reap the natural resources and leaving back not an ounce of guilt, for a country’s social and economic instability caused by their actions. Industries like manufacturing, pharmaceutical and oil refinery, many corporations contribute to the injustice of violating human rights and the environment. As the business world and economy evolves into a free market enterprise, many corporations continue to demonstrate poor business practices and it is becoming difficult to hold them liable for their actions. Many corporations are also being very silent about their unjust business practices and have many ways to cover up any reported abuse. Countries that experience environmental violations, should impose strict regulatory policies so......

Words: 2141 - Pages: 9

Merck Case

...que repercutió en el desplome del rendimiento de activos de dicha empresa, hasta antes de la conformación de un comité de estudio para mejorar resolver dicha problemática en el año de 1985. Merck & Co., es una farmacéutica que tuvo sus inicios en Alemania en 1668; en el año de 1887 apertura su sucursal en la ciudad de New York, Estados Unidos; en primera instancia para comercializar los productos alemanes, posterior a ello se dedicó a fabricar medicamentos y productos químicos que hasta la actualidad gozan de fama y prestigio. Merck & Co., ocupó titulares de renombre y gozó de prestigiosos premios, además de la fama que incluían su solidez financiera, calidad en sus productos, innovación, y capacidad para desarrollar talento de su personal, su rentabilidad era superior a las otras corporaciones de su medio. Sin embargo y pese al éxito, en 1983 Merck & Co., empezó a experimentar un declive en sus activos, el rendimiento de la misma quedó rezagada en esa fecha, debido a varios factores económicos del medio, y del descontento existente entre el personal debido a la aplicación no adecuada del sistema de medición del desempeño por ende de las recompensas. Introdujo por primera vez en 1978 el programa de administración de salarios y evaluación del desempeño de Merck, en el que los supervisores evaluaban en una escala del 1 al 5 a sus empleados, designando al 1 como rendimiento inaceptable y 5 como rendimiento excepcional. La escala era absoluta y la......

Words: 1532 - Pages: 7

Merck Case

...suffering from the disease or those who potentially may be infected – would directly benefit from the cure Merck employees at all levels – profitability and the economic health of the company affects current employees Merck shareholders – inability to profit from the drug might have a negative effect on shareholder’s value, but taking the stand on “doing the right thing” might have a favorable effect on company’s reputation and increase the value of the stock Various healthcare organizations – Merck is one of the leaders in the industry whose actions or inactions may affect the state of the industry as a whole One way to rank stakeholders in importance is by their level of benefit from the drug putting people suffering from the disease in the first place as they would benefit the most from the invent of the cure. Then, employees and shareholders would share the second place, provided that the company would most likely not be able to recover funds invested in the long and expensive process of developing the drug which in turn would affect company’s profitability. Finally, various healthcare organizations would rank third; the effect on them would depend on the level of their involvement in the process. 2. What are the potential costs and benefits of such an investment? Developing a drug to combat river blindness has substantial potential costs and befits. Merck discovered an opportunity to treat millions of affected people around the world but it knew that the......

Words: 321 - Pages: 2

Case Study

...Unit 1 Case Study F.C. is a 54-year-old man with a history of chronic heavy alcohol use. He has frequent bouts of gastrointestinal bleeding for which he has been hospitalized on six separate occasions over the years. He continues to drink and exhibits most of the common manifestations of alcoholic cirrhosis. He was recently hit by a car and was hospitalized for a broken leg. He appeared to be under the influence of alcohol at the time of the accident and had a blood alcohol level of 0.18. F.C.’s family reports that his mental functioning has deteriorated significantly over the past few months.  Discussion Questions 1. What are the common manifestations of alcoholic cirrhosis? Which of these are secondary to hepatocellular failure? Which are secondary to portal hypertension? - The effects of alcohol depend on the level of alcohol consumption and how long the person has been drinking alcohol as well. Common manifestations of alcoholic cirrhosis vary however jaundice, vomiting, fever, nausea and portal hypertension are the most common symptoms. Jaundice is a symptom that is secondary to hepatocellular failure. When jaundice occurs, the bilirubin metabolic cycle is impaired due to the breakdown of cells within the liver tissue. The destruction of these cells enables bilirubin to decrease and not be inherited correctly. Portal hypertension is caused cirrhosis. Vascular resistance and blood flow play an essential role in the development. The complication arises as a......

Words: 637 - Pages: 3

Case Study

...Merck, the FDA, and the Vioxx Recall In 1999 the Food and Drug Administration (FDA) had approved Vioxx, what would become Merck’s “blockbuster” drug. Although the FDA had approved the drug there was uncertainty of the safety of drug. Vioxx was approved to treat a variety of conditions, such as osteoarthritis and acute pain, but there was also a chance that it would increase cardiovascular problems. What I found most interesting about this case was the changes in how drugs are brought to consumers, from how they are approved to how they are informed of the drug. Strengths Merck was heading in the right direction with its drug Vioxx. They wanted the drug to be a “blockbuster”, used for multiple symptoms and everyday use. Merck used direct-to-consumer advertising to fuel sales of Vioxx. Vioxx seemed to benefit stakeholders on both ends of the spectrum, until it was found to cause cardiovascular problems. Merck did continue to research the effects of its drug and eventually voluntarily withdrew Vioxx. This is a strength in that they made the right ethical decision to withdraw the drug, even though it did take almost 5 years. Weaknesses Merck’s weakness would be that it did not research its drug thoroughly enough for possible problems before seeking approval from the FDA. The FDA etimates that 139,000 people in the United States had had a heart attack or stroke as a result of taking VIoxx. This could have been prevented if Merck had properly researched the drug or......

Words: 548 - Pages: 3

Merck Case Solution

...Protect Veterinary Business Merck Should Develop Companies do not justify every investment to shareholders, so we are not convinced that they would need to justify this one. But, they certainly would not be able to justify it in terms of the financial bottom line. They would have to justify it in terms of goodwill, or some other more difficult to measure criterion. Cost of development of human drug is less as when they had to find for new drug That if other organizations decided to go on their own and produce and distribute Mectizan without Merck, the cost of production would be significantly higher for them than for Merck due to the need to invest in production facilities. To be conservative, we assume that their cost savings in distribution are cancelled out due to the excess costs in production and therefore they have the same total cost as Merck. By running this program, Merck also do benefit from many intangible features by associating its brand with such sensitive public cause. Among these intangible benefits there are: Public Relations: It is important to highlight that although this program was run in Africa, where the consumer market in terms or revenues is not as big as in the developed countries, this program was able to generate huge traction among several important media companies around the world and millions of people were "impacted" by the program features. Although it is hard to quantify, there is no doubt that Merck brand equity was leveraged......

Words: 776 - Pages: 4

Merck Case

...Conflict and Change Harvard Case Study Professor: Robert Lazer PhD Team: Zerrin Hejazi, Mark Klabonski, Elizabeth Lamb, Hari Thenneti Pandurangamoorthi, & Hareshkumar Surani The History of Merck U.S. sales office opened in and George Merck, Heinrich’s grandson, was appointed head of the U.S. branch Friedrich Jacob Merck opened Merck in Germany 1668 1827 Heinrich E Merck transformed the business and Merck began manufacturing 1887 Merck merged with Philadelphia pharmacy Sharp & Dohme 1891 The renamed company Merck & Co. opens for business 1953 2009 Merck merged with ScheringPlough Corporation and Organon BioSciences Pharmaceutical Industry • The average drug development time is over fifteen years with an average R&D expenditure of $800 million. • The FDA requires three phases of testing to assess safety and effectiveness. o Test results dictate what is displayed on the drug’s label and how the doctor will prescribe it. • Follow-up studies (Phase 5) can be performed to assess the drug after market release (Phase 4) and amend the drug label for improved sales. Pharmaceutical Success • 1981 to 2001, Merck experienced an upward trend on several industry metrics. • Their Return on Sales (ROS) for their Human Pharma line peaked at just over 40% in 2001 with an average of 24% . • The early 1990’s exhibited a downward trend just prior to Gilmartin assuming the role of CEO. Pharmaceutical......

Words: 3826 - Pages: 16

Merck and Lab Pharmaceuticals Case Study

...Business description In 2000 Merck is a successful pharmaceutical company with a handful of drugs developed internally as well as in joint-ventures. Its success however linked to the exclusivity rights of its patents, which makes its investors concerned about the close expiration (2002) of several patents of its blockbusters, which would dry out future revenues. The long-term viability of the company depends thus on the ability to refresh its portfolio of patent-protected drugs in order to counterbalance the loss of sales resulting from the generics. The large financial capacity of Merck & Co enables the company to buy rights to test, manufacture and market compounds which were generated by smaller companies which lack the capital or want to avoid the risk; in case the FDA is successfully completed Merck & Co. profits by having bought the patent at a cheap price. In this context a young pharma company, LAB Pharmaceuticals has approached Merck offering them to license one of their compounds called Davanrik. The company is in an uncomfortable financial situation and hesitates to launch the testing of this promising Davanrik, a drug whose use could be dual for weight and depression problems. Davanrik has already successfully completed the preclinical testing and has to complete the approval phases 1 to 3 and the final FDA approval. LAB proposed to Merck to be in charge of the approval of Davanrik, its manufacture and its marketing and would in exchange pay to LAB an initial fee,...

Words: 1029 - Pages: 5

Merck Case - Business Ethic

...Vagelos as CEO and for Merck as a company in deciding whether to invest in Dr. Campbell’s idea? The stakes for Roy Vagelos as CEO would be the high level of risk to succeed, the strong change to have a low level of profitability even after the success, and the advantage of Dr Campbell’s project, less investment needed and government aid in tax. And the stakes for Merck as a company would be the corporate ethic it has pursued and Merck’s need to develop another new successful prescription. Q2. How does Merck pick from among the many ways to “do good” and many drugs to invest in? Merck took 12 years and $200 million to bring a new drug to market on the average. And thousands of scientists worked on new ideas and following new leads. It uses various methods to choose the project through extensive review and analysis on the basis of the likelihood of success, the existing market, competition, potential safety problems, manufacturing feasibility and patent. Q3. How much of its research budget should Merck invest in drugs that will likely produce a substandard return on its investment? The research budget should be considered in research/development expenses, expected income with the tax benefit from the government, and mostly the effect and impact based on the corporate ethics and morale. Q4. What should Merck tell a shareholder who might complain about a decision to invest in research on river blindness? The overall corporate philosophy of Merck is based on......

Words: 336 - Pages: 2